Disease · MONDO_0001416

female reproductive organ cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. female reproductive organ cancer. Diseases, record MONDO_0001416. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001416

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: female reproductive organ cancer; Open Targets
Open Targets ID: MONDO_0001416; Open Targets
Other names: Genital neoplasm, female, cancer of female reproductive organ, female reproductive cancer, gynecologic cancer, malignant female reproductive organ neoplasm, malignant female reproductive system neoplasm, malignant female reproductive system tumor, malignant female reproductive system tumour, malignant gynecologic neoplasm, malignant gynecologic tumor, malignant gynecologic tumour, malignant neoplasm of female genital organ, malignant neoplasm of female reproductive organ, malignant neoplasm of female reproductive system, malignant neoplasm of the female reproductive system, malignant tumor of female reproductive system, malignant tumor of the female reproductive system, malignant tumour of female reproductive system, malignant tumour of the female reproductive system; Open Targets
Disease Ontology: DOID:120; Disease Ontology
NCI Thesaurus: C4913; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 13 of its 33 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs33

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FULVESTRANT	CHEMBL1358	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
PALBOCICLIB	CHEMBL189963	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ABEXINOSTAT	CHEMBL2103863	Small molecule	Phase 2	TTD	2	1	0	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NERATINIB	CHEMBL180022	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 33

See all 33 drugs

Targets105

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/5156	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 105

See all 105 targets

Trials21

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01209195	A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers	Phase 1	41	2016-09-08	Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer	PACLITAXEL, SERIBANTUMAB	Its record names the disease	ClinicalTrials.gov
NCT01588522	Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia	Phase 1	28	2025-05-28	Chemotherapy-Induced Alopecia	CALCITRIOL	Its record names the disease	ClinicalTrials.gov
NCT07024784	A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies	Phase 2	377		Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)	BEVACIZUMAB, CARBOPLATIN, OLAPARIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01226316	Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	Phase 1	285		Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive	CAPIVASERTIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	Phase 2	270		Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer	BEVACIZUMAB, RELACORILANT	Open Targets' reading of its record	ClinicalTrials.gov
NCT05448586	Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?		132		Cervix Cancer, Endometrial Cancer, Ovarian Cancer, Breast Cancer	DEXMEDETOMIDINE, KETAMINE, LIDOCAINE, PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT06126276	Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	Phase 2	70		Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm	NERATINIB, PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT04273061	Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity	Phase 2	50		Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04760327	Electrochemotherapy of Gynecological Cancers	Phase 2	30		Gynecological Cancers	BLEOMYCIN, CISPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00842452	Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery	Phase 1	26		Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer	TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 21

See all 21 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
MM-121 + Paclitaxel: Dose Escalation vs MM-121 + Paclitaxel: Expansion Cohort: serious adverse events	4 of 10	12 of 31	41	NCT01209195

Source Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31298153	RESULT	1	PubMed
30252709	RESULT	1	PubMed
28922235	RESULT	1	PubMed
26497721	RESULT	1	PubMed
22510347	RESULT	1	PubMed
40273550	DERIVED	1	PubMed
34250397	DERIVED	1	PubMed
33863913	DERIVED	1	PubMed
32312891	DERIVED	1	PubMed
29066505	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001416

GET https://conductscience.org/api/diseases/v1/MONDO_0001416/drugs?page=2

API reference For AI assistants